Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.
about
Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.
P2860
Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@en
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@nl
type
label
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@en
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@nl
prefLabel
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@en
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
Tumor stromal disrupting agent ...... ated liposomes in lung cancer.
@en
P2093
Cedar Ha Boakye
Ketan Patel
Mandip Singh
Nusrat Chowdhury
Ravi Doddapaneni
P2860
P304
P356
10.2217/NNM.16.37
P50
P577
2016-05-12T00:00:00Z